{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T18:16:16Z","timestamp":1694628976682},"reference-count":22,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T00:00:00Z","timestamp":1575504000000},"content-version":"vor","delay-in-days":4631,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1093\/annonc\/mdm065","type":"journal-article","created":{"date-parts":[[2007,3,14]],"date-time":"2007-03-14T00:05:15Z","timestamp":1173830715000},"page":"615-618","source":"Crossref","is-referenced-by-count":2,"title":["The treatment of lymphoma complicating autoimmune disease: two birds with one stone?"],"prefix":"10.1016","volume":"18","author":[{"given":"T.R.","family":"Mikuls","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdm065_bb0010","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S1521-6942(03)00041-X","article-title":"Co-morbidity in rheumatoid arthritis","volume":"17","author":"Mikuls","year":"2003","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1093\/annonc\/mdm065_bb0015","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1158\/1055-9965.EPI-06-0300","article-title":"Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics","volume":"15","author":"Smedby","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1093\/annonc\/mdm065_bb0020","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1002\/art.10679","article-title":"Tumor necrosis factor antagonist therapy and lymphoma development","volume":"46","author":"Brown","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1093\/annonc\/mdm065_bb0025","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdl467","article-title":"Influence of rituximab, cyclophosphamide, doxobubicin, vincristine and prednisone on serologic parameters and clinical course in lymphoma patients with autoimmune diseases","author":"Wohrer","year":"2007","journal-title":"Ann Oncol"},{"issue":"Suppl","key":"10.1093\/annonc\/mdm065_bb0030","first-page":"s303","article-title":"Lymphoma characteristics in the context of rheumatoid arthritis: case series from the Nebraska Lymphoma Study Group Registry","volume":"50","author":"Endo","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1093\/annonc\/mdm065_bb0035","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V99.11.3909","article-title":"Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France","volume":"99","author":"Mariette","year":"2002","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdm065_bb0040","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1093\/annonc\/mdm065_bb0045","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/art.1780251101","article-title":"The 1982 revised criteria for the classification of systemic lupus erythematosus","volume":"25","author":"Tan","year":"1982","journal-title":"Arthritis Rheum"},{"key":"10.1093\/annonc\/mdm065_bb0050","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1136\/ard.49.11.916","article-title":"Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score","volume":"49","author":"Van der Heijde","year":"1990","journal-title":"Ann Rheum Dis"},{"key":"10.1093\/annonc\/mdm065_bb0055","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/rheumatology\/kel098","article-title":"Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab","volume":"45","author":"Stasi","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1093\/annonc\/mdm065_bb0060","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ard.2006.057919","article-title":"Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome","volume":"66","author":"Seror","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1093\/annonc\/mdm065_bb0065","unstructured":"U.S. Food and Drug Administraion. FDA news: FDA warns of safety concern regarding Rituxan in new patient populationhttp:\/\/www.fda.gov\/bbs\/topics\/NEWS\/2006\/NEW01532.html (22 January 2007, date last accessed)"},{"key":"10.1093\/annonc\/mdm065_bb0070","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/art.11181","article-title":"Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis","volume":"48","author":"Cambridge","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1093\/annonc\/mdm065_bb0075","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdm065_bb0080","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/art.1780360601","article-title":"The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials","volume":"36","author":"Felson","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1093\/annonc\/mdm065_bb0085","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/art.21675","article-title":"Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis","volume":"54","author":"Baecklund","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1093\/annonc\/mdm065_bb0090","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1200\/JCO.2005.04.6227","article-title":"Prospective study of survival outcomes in non-Hodgkin's lymphoma patients with rheumatoid arthritis","volume":"24","author":"Mikuls","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm065_bb0095","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/rheumatology\/38.7.668","article-title":"Extra-articular rheumatoid arthritis; prevalence and mortality","volume":"38","author":"Turesson","year":"1999","journal-title":"Rheumatology (Oxford)"},{"key":"10.1093\/annonc\/mdm065_bb0100","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/bmj.317.7152.180","article-title":"Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study","volume":"317","author":"Baecklund","year":"1998","journal-title":"BMJ"},{"issue":"Suppl","key":"10.1093\/annonc\/mdm065_bb0105","first-page":"S188","article-title":"Inflammatory activity, but not methotrexate or prednisone use predicts non-Hodgkin's lymphoma in rheumatoid arthritis: a 25-year study of 1,767 RA patients [abstract]","volume":"41","author":"Wolfe","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1093\/annonc\/mdm065_bb0110","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.1002\/art.22277","article-title":"Characteristics of diffuse large B cell lymphoma in rheumatoid arthritis","volume":"54","author":"Baecklund","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1093\/annonc\/mdm065_bb0115","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1136\/ard.2004.034504","article-title":"Non-Hodgkin's lymphoma in systemic lupus erythematosus","volume":"64","author":"Bernatsky","year":"2005","journal-title":"Ann Rheum Dis"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419378858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419378858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/18\/4\/615\/310685\/mdm065.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T17:00:31Z","timestamp":1635786031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419378858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["S0923753419378858"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdm065","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}